The Michael J. Fox Foundation for Parkinson's Research has been
playing at all stages of the development spectrum. Most recently it has granted
$2.4 million to fund research into repurposing marketed drugs to treat
Parkinson's disease and is collaborating on the development of a new mouse
model for the indication that will be freely available to researchers.
Haas, M.J. SciBX 4(29); doi:10.1038/scibx.2011.813 Published
online July 28, 2011
1. Djaldetti, R. et al.
Clin. Neuropharmacol. 30, 201-205 (2007)
2. Hansen, S. BioCentury
18(41), A6-A7; Sept. 20, 2010
3. Lee, K.-W. et al.
J. Neurosci. 31, 6963-6971 (2011)
4. Haas, M.J. SciBX 4(21); doi:10.1038/scibx.2011.590
5. Vilariño-Güell, C. et
al. Am. J. Hum. Genet. 89, 162-167 (2011)
AND INSTITUTIONS MENTIONED
Addex Pharmaceuticals Ltd. (SIX:ADXN), Geneva, Switzerland
Asahi Kasei Pharma Corp., Tokyo, Japan
Beilinson Hospital, Petah Tikva, Israel
Elan Corp. plc (NYSE:ELN), Dublin, Ireland
Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind.
Lund University, Lund, Sweden
McLean Hospital, Belmont, Mass.
Melior Discovery Inc., Exton, Pa.
The Michael J. Fox Foundation for Parkinson's Research, New York, N.Y.
Michigan State University, East Lansing, Mich.
National Institute on Aging, Bethesda, Md.
National Institute on Drug Abuse, Bethesda, Md.
National Institutes of Health, Bethesda, Md.
NeuroHealing Pharmaceuticals Inc., Newton, Mass.
Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
Pfizer Inc. (NYSE:PFE), New York, N.Y.
reMYND N.V., Leuven, Belgium
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
Signum Biosciences Inc., Monmouth Junction, N.J.
The University of British Columbia, Vancouver, British Columbia, Canada
University of California, Los Angeles, Calif.
Van Andel Institute, Grand Rapids, Mich.